Promoting research partnerships to improve veterans’ health

NAVREF is proud to recognize Cohen Veterans Bioscience as our Champion Sponsor

DoD Kidney Cancer Research Program Funding Opportunities

21 Jun 2022 11:11 AM | Anonymous member (Administrator)

The FY22 Defense Appropriations Act is anticipated to provide funding for the KCRP to support research of exceptional scientific merit in the area of kidney cancer.  The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY22 KCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website. 

 

Applications submitted to the FY22 KCRP must address one or more of the following Focus Areas:

 

  • Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors and the prevention of kidney cancer.
  • Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
  • Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
  • Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
  • Identify and implement strategies to improve the quality of life and survivorship for patients.
  • Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
  • Support preparation and development of the next generation of kidney cancer researchers, or cultivate collaborations in kidney cancer research or patient care in alignment with the KCRP Overarching Strategic Goals.

Funding Opportunities - FY22 Kidney Cancer Research Program, Congressionally Directed Medical Research Programs (CDMRP) (army.mil)

Academy of Kidney Cancer Scholars – Early-Career Investigator Award – Letter of Intent September 29, 2022

Must be within 4 years of last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent, as of full application submission deadline.

Letter attesting to eligibility required.

·        Supports the addition of new Early-Career Scholars to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.

·        Early-Career Scholars whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

·        A Designated Mentor who is an experienced kidney cancer researcher with a record of kidney cancer funding is required.

·        The Designated Mentor not required to be at the same institution as the Early-Career Scholar.

·        Preliminary data required.

·        Clinical trials are not allowed.

·        Maximum funding of $725,000 for direct costs (plus indirect costs).

·        Maximum period of performance 4 years.

·        Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Nurse-Initiated Research Award – Letter of Intent due September 29, 2022

Must have a Registered Nurse license and/or a Master’s or Doctoral degree in nursing.

  • Supports nursing research pertaining to kidney cancer patient care.
  • Clinical trials are not allowed; correlative studies to clinical trials are allowed. Qualified Collaboration Option: Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.
  • •Maximum funding of $300,000 for direct costs (plus indirect costs).
  • •Maximum period of performance is 2 years.
  • •Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Clinical Trial Award Modified for FY22 – Letter of Intent due September 29, 2022

Independent investigators at all levels.

                  Supports projects ranging from small proof-of-concept trials (e.g., pilot, first in human, phase 0) to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

                  Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies.

                  Investigational New Drug (IND) or Investigational Device Exemption (IDE) application, if applicable, must be submitted to the U.S. Department of Food and Drug Administration (FDA) by the time of application submission.

                  Documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study must be provided.

                  Clinical trials are expected to begin no later than 12 months after the award date, or 18 months after the award date for FDA-regulated studies.

                  Qualified Collaboration Option: Leveraging of existing infrastructure of a federally funded partnership/consortium is encouraged.

                  Maximum funding of

·       $1,500,000 for direct costs (plus indirect costs).

                  Maximum period of performance is 4 years.

                  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·       Cell Therapy Focus Option:

                  Maximum funding of

·       $2,000,000 for direct costs (plus indirect costs).

                  Maximum period of performance is 4 years.

                  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Concept Award – Letter of Intent due June 23, 2022

                  All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.

                  Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer.

                  Emphasis on innovation.

                  Preliminary data are not allowed.

                  Clinical trials are not allowed.

                  Blinded review.

                  Maximum of $100,000 for direct costs (plus indirect costs).

                  Maximum period of performance is 1 year. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Idea Development Award Modified for FY22 – Preproposal due June 2, 2022

Established Investigators: 

Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree.

Early-Career Investigators:

Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency/fellowship or family medical leave) at the time of application submission deadline.

·      Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

·      Preliminary data required.

·      Innovation and impact are the most important review criteria.

·      Clinical trials are not allowed.

Different funding options, based on the scope of proposed research, are available with compelling justification. .  Maximum funding of $675,000 in direct costs (plus indirect costs).

·      Maximum period of performance 3 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

·      Early Detection Studies Option: 

·      Maximum funding of $700,000 in direct costs (plus indirect costs).

·      Maximum period of performance 3 years.

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Population Science and Prevention Studies Option:

·      Maximum funding of $2 million in direct costs (plus indirect costs)

·      Maximum period of performance 4 years

·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Postdoctoral and Clinical Fellowship Award – Letter of Intent due June 23, 2022

Must have completed requirements for a Ph.D. and/or M.D.  

Must be in the laboratory or clinical setting where proposed research will be performed.

Must have no more than 4 years of postdoctoral and/or mentored clinical research experience.

Investigators in non-postdoctoral and/or clinical fellow positions are not eligible.

                  Supports research opportunities focused on kidney cancer for individuals in the early stages of their careers.

                  A designated mentor who is an experienced kidney cancer researcher is required.

                  Clinical trials are not allowed.

                  Maximum funding of $195,000 for direct costs (plus indirect costs).

                  Maximum period of performance is 3 years.

                  Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

Translational Research Partnership Award – Preproposal due June 2, 2022

The Initiating Principal Investigator (PI) must be at or above the level of Assistant Professor or equivalent.

The Partnering PI must be at or above the level of Assistant Professor or equivalent. 

Postdoctoral fellows are not eligible to be Partnering PIs.

•Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications.

•Supports translational correlative studies.

•Preliminary data are required.

•Clinical trials are not allowed.

•Maximum funding of $750,000 for direct costs (plus indirect costs).

•Maximum period of performance is 3 years.

•Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org



1717 K ST NW Suite 900

Washington, DC 20006

202-951-7701  |  admin@navref.org

Powered by Wild Apricot Membership Software